Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MAGEE1 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5103463
Description
Antibody detects endogenous levels of total MAGE1.
This gene encodes an alpha-dystrobrevin-associated MAGE (melanoma-associated antigen) protein, which is a member of the MAGE family. The protein contains a nuclear localization signal in the N-terminus, 30 12-amino acid repeats beginning at nt 60 with the consensus sequence ASEGPSTSVLPT, and two MAGE domains in the C-terminus. It may play a signaling role in brain, muscle, and peripheral nerve. This gene is located on X chromosome in a region containing loci linked to cognitive disability.
Specifications
| MAGEE1 | |
| Polyclonal | |
| Unconjugated | |
| MAGEE1 | |
| AI847422; Alpha-dystrobrevin-associated MAGE Protein; DAMAGE; dystrobrevin-associated MAGE protein; HCA1; hepatocellular carcinoma-associated HCA1; hepatocellular carcinoma-associated protein 1; hepatocellular carcinoma-associated protein HCA1; KIAA1587; MAGE family member E1; Magee1; MAGE-E1 antigen; melanoma antigen family E, 1; melanoma antigen family E1; melanoma antigen, family E, 1; melanoma-associated antigen E1; mMage-e1; RGD1560259 | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 107528, 317232, 57692 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| A1A5P9, Q6PCZ4, Q9HCI5 | |
| MAGEE1 | |
| A synthesized peptide derived from human MAGEE1(Accession Q9HCI5), corresponding to amino acid residues E716-I766. | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction